NEW YORK (GenomeWeb) – John Hopkins University spinout Personal Genome Diagnostics plans to develop cancer diagnostic products that it will bring through US Food and Drug Administration clearance.

At last week's Molecular Medicine Tri-Conference in San Francisco, PGDx Founder and CSO Victor Velculescu told GenomeWeb that the company is in the midst of "moving from being a service company to a product company," and aims to bring both tissue-based targeted sequencing tests as well as NGS-based liquid biopsy tests through FDA clearance in the next couple of years.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.